Susan Bal, MD, on Favorable Safety of BMS-986393 in R/R Multiple Myeloma

“The data we shared today was really encouraging. I think that it has really shown, at least in the follow up so far, to be a very effective and relatively safe novel agent that can target GPRC5D. And as we understand the sequencing better, we'll be able to further define where in the treatment landscape this fits.”

BMS-986393 (Bristol Myers Squibb), a GPRC5D-targeted chimeric antigen receptor (CAR) T-cell therapy, has shown efficacy in patients with relapsed/refractory multiple myeloma (RRMM) with a manageable safety profile according to new data from a phase 1, first in human trial (NCT04674813). Efficacy was seen across patient subgroups, including patients that had received prior anti-BCMA therapy and/or had high-risk cytogenetics (around 50% for both subgroups). The most frequent adverse event was cytopenia.

Susan Bal, MD, assistant professor of medicine at University of Alabama – Birmingham, presented the updated data at the European Hematology Association (EHA) 2023 Congress, held June 8-11, both virtually and in Frankfurt, Germany.

CGTLive’s sister site, OncLive, spoke with Bal to learn more about BMS-986393 and its potential benefit in patients with RRMM. She shared her positive view on the CAR T-cell therapy and its potential future in the treatment landscape of RRMM. She alsooverviewed the study and patient demographics and stressed the favorable safety profile observed.

Click here for more coverage of EHA 2023.

REFERENCE

Bal S, Berdeja J, Htut M, et al. BMS-986393 (CC-95266), A G protein–coupled receptor class C GROUP 5 member D (GPRC5D)–targeted CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM): results from a phase 1 study. Presented at: EHA 2023 Congress. Abstract #S193